Full Press Release Details
PellePharm Presents Updated Data From Two Phase 2 Studies Demonstrating The Potential Of Patidegib Topical Gel To Treat Basal Cell Carcinomas In Patients With Gorlin Syndrome And Patients With Non-Gorlin Sporadic BCCs.
BBIO
PellePharm Presents Updated Data From Two Phase 2 Studies Demonstrating The Potential Of Patidegib Topical Gel To Treat Basal Cell Carcinomas In Patients With Gorlin Syndrome And Patients With Non-Gorlin Sporadic BCCs
Key Takeaway: PellePharm Presents Updated Data From Two Phase 2 Studies Demonstrating The Potential Of Patidegib Topical Gel To Treat Basal Cell Carcinomas In Patients With Gorlin Syndrome And Patients With Non-Gorlin Sporadic BCCs
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+41%
120-day peak, hindsight
Typical move
3.6%
average across 13 past catalysts
Cash runway
~30 mo
Minimal dilution risk
Lead asset
acoramidis
Phase 3 · Amyloidosis